![PRODIGE23, long term results now published](https://oncodaily.com/pub/uploads/2024/07/IMG_3950-1280x842.jpeg)
Photo taken from news-medical.net
Jul 12, 2024, 17:25
PRODIGE23, long term results now published
Krishan Jethwa, Assistant Professor of Radiation Oncology at Mayo Clinic, shared a paper by Thierry Conroy et al. on X:
“PRODIGE23.
Long term results now published!
T3-4 rectal adenocarcinoma Randomized:
CRT to FOLFOX mFOLFIRINOX to CRT to FOLFOX
Improved OS!!!
Looking forward to JANUS clarifying if TNT with FOLFIRINOX vs. FOLFOX improves cCR and/or DFS/OS.”
Source: Krishan Jethwa/X
Authors: T. Conroy, F. Castan, P.-L. Etienne, E. Rio, N. Mesgouez-Nebout, L. Evesque, V. Vendrely, X. Artignan, O. Bouché, D. Gargot, V. Boige, N. Bonichon-Lamichhane, C. Louvet, C. Morand, C. de la Fouchardière, A. Boilève, M. Delaye, S. Gourgou, V. Pezzella, and C. Borg.
A. Boilève
C. Borg
C. de la Fouchardière
C. Louvet
C. Morand
cancer
D. Gargot
E. Rio
F. Castan
FOLFIRINOX
FOLFOX
JANUS
Krishan Jethwa
L. Evesque
M. Delaye
N. Bonichon-Lamichhane
N. Mesgouez-Nebout
O. Bouché
OncoDaily
Oncology
P.-L. Etienne
PRODIGE23
rectal adenocarcinoma
S. Gourgou
Thierry Conroy
V. Boige
V. Pezzella
V. Vendrely
X. Artignan
Aug 26, 2024, 06:10